Dithranol
Based on 1 Customer Validation
Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.26%
- CAS No.: 1143-38-0
- Formule: C14H10O3
- Masse moléculaire:226.23
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | GI50 |
0.7 μM
Compound: 14
|
Growth inhibition of human HaCaT cells after 72 hrs by neutral red uptake assay
Growth inhibition of human HaCaT cells after 72 hrs by neutral red uptake assay
|
[PMID: 22944332] |
| HaCaT | IC50 |
0.2 μM
Compound: anthralin
|
Antiproliferative activity against HaCaT cells
Antiproliferative activity against HaCaT cells
|
[PMID: 8201600] |
| HaCaT | IC50 |
0.6 μM
Compound: 1/ Anthralin
|
Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)
Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)
|
[PMID: 9371243] |
| HaCaT | IC50 |
0.6 μM
Compound: anthralin
|
Antiproliferative activity (AA) against HaCaT keratinocytes.
Antiproliferative activity (AA) against HaCaT keratinocytes.
|
[PMID: 9276024] |
| HaCaT | IC50 |
0.7 μM
Compound: 1
|
Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
|
[PMID: 20452101] |
| HaCaT | IC50 |
0.7 μM
Compound: 1
|
Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
|
[PMID: 20828887] |
| HaCaT | IC50 |
0.7 μM
Compound: 2
|
Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis
Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis
|
[PMID: 26840368] |
| HaCaT | IC50 |
0.7 μM
Compound: 2, Anthralin
|
Antiproliferative activity against human HaCaT cells assessed as dispersed cells after 48 hrs by phase-contrast microscopic analysis
Antiproliferative activity against human HaCaT cells assessed as dispersed cells after 48 hrs by phase-contrast microscopic analysis
|
[PMID: 20850910] |
| HaCaT | IC50 |
0.7 μM
Compound: 3
|
Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
|
[PMID: 22845014] |
| HaCaT | IC50 |
0.7 μM
Compound: 5
|
Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy
Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy
|
[PMID: 24964246] |
| HaCaT | IC50 |
0.7 μM
Compound: Anthralin
|
Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay
Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay
|
[PMID: 28410493] |
| HaCaT | IC50 |
0.7 μM
Compound: 1
|
Concentration required to inhibit 50% growth of HaCaT cells
Concentration required to inhibit 50% growth of HaCaT cells
|
[PMID: 11262091] |
| HaCaT | IC50 |
0.7 μM
Compound: 1
|
In vitro for antiproliferate activity against HaCaT cells
In vitro for antiproliferate activity against HaCaT cells
|
[PMID: 9873705] |
| HaCaT | IC50 |
0.7 μM
Compound: 1; DTR; dithranol
|
Antiproliferative activity against human HaCaT cells
Antiproliferative activity against human HaCaT cells
|
[PMID: 26515039] |
| HaCaT | IC50 |
0.7 μM
Compound: anthralin
|
Antiproliferative activity against human HaCaT cells
Antiproliferative activity against human HaCaT cells
|
[PMID: 10395495] |
| HaCaT | IC50 |
0.7 μM
Compound: Anthralin
|
Antiproliferative activity against human HaCaT cells
Antiproliferative activity against human HaCaT cells
|
[PMID: 10479319] |
| HaCaT | IC50 |
0.7 μM
Compound: Anthralin
|
Antiproliferative activity against growth of HaCaT cell was determined
Antiproliferative activity against growth of HaCaT cell was determined
|
[PMID: 11140730] |
| HaCaT | IC50 |
0.945 μM
Compound: 1; DTR; dithranol
|
Antiproliferative activity against human HaCaT cells after 24 hrs by MTT assay
Antiproliferative activity against human HaCaT cells after 24 hrs by MTT assay
|
[PMID: 26515039] |
| HaCaT | IC50 |
2.9 μM
Compound: anthralin
|
Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation after 24 hrs
Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation after 24 hrs
|
[PMID: 15387642] |
| HaCaT | IC50 |
3.52 μM
Compound: Anthralin
|
Antiproliferative activity against human HaCaT cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HaCaT cells incubated for 48 hrs by MTT assay
|
[PMID: 39151117] |
| HEK293 | GI50 |
0.5 μM
Compound: 14
|
Growth inhibition of human NHEK cells after 72 hrs by neutral red uptake assay
Growth inhibition of human NHEK cells after 72 hrs by neutral red uptake assay
|
[PMID: 22944332] |
| PMNL | IC50 |
37 μM
Compound: anthralin
|
Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells
Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells
|
[PMID: 10395494] |
| THP-1 | GI50 |
54 μM
Compound: 14
|
Growth inhibition of human THP1 cells after 72 hrs by Cell Titer 96 aqueous one solution assay
Growth inhibition of human THP1 cells after 72 hrs by Cell Titer 96 aqueous one solution assay
|
[PMID: 22944332] |
| U-937 | GI50 |
5 μM
Compound: 14
|
Growth inhibition of human U937 cells after 72 hrs by Cell Titer 96 aqueous one solution assay
Growth inhibition of human U937 cells after 72 hrs by Cell Titer 96 aqueous one solution assay
|
[PMID: 22944332] |
Dithranol (1.1 μM) inhibits replication in T98G cells by 50%[2].
?
Dithranol (0.1-0.5 μg/mL; 2-4 hours) increases the mRNA production of interleukin-10 receptors in a concentration dependent manner in HaCaT cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HaCaT cells
-
Concentration:0.1 μg/mL, 0.25 μg/mL, 0.5 μg/mL
-
Incubation Time:2 hours, 4 hours
-
Result:Increased the mRNA production of interleukin-10 receptors in HaCaT cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1143-38-0
-
Appearance Solid
-
Masse moléculaire 226.23
-
Formule C14H10O3
-
Color Yellow to orange
-
SMILES
O=C1C2=C(C=CC=C2O)CC3=CC=CC(O)=C13
-
Synonyms
Anthralin
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 20 mg/mL (88.41 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1 mg/mL (4.42 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1 mg/mL (4.42 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. L Kemény , et al. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 1990;3(1):1-20. [Content Brief]
[2]. J M Clark, et al. Inhibition of DNA replication and repair by anthralin or danthron in cultured human cells. J Invest Dermatol. 1982 Jul;79(1):18-22. [Content Brief]
[3]. A Farkas, et al. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm Res. 2001 Jan;50(1):44-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.4203 mL | 22.1014 mL | 44.2028 mL | 110.5070 mL |
| 5 mM | 0.8841 mL | 4.4203 mL | 8.8406 mL | 22.1014 mL | |
| 10 mM | 0.4420 mL | 2.2101 mL | 4.4203 mL | 11.0507 mL | |
| 15 mM | 0.2947 mL | 1.4734 mL | 2.9469 mL | 7.3671 mL | |
| 20 mM | 0.2210 mL | 1.1051 mL | 2.2101 mL | 5.5254 mL | |
| 25 mM | 0.1768 mL | 0.8841 mL | 1.7681 mL | 4.4203 mL | |
| 30 mM | 0.1473 mL | 0.7367 mL | 1.4734 mL | 3.6836 mL | |
| 40 mM | 0.1105 mL | 0.5525 mL | 1.1051 mL | 2.7627 mL | |
| 50 mM | 0.0884 mL | 0.4420 mL | 0.8841 mL | 2.2101 mL | |
| 60 mM | 0.0737 mL | 0.3684 mL | 0.7367 mL | 1.8418 mL | |
| 80 mM | 0.0553 mL | 0.2763 mL | 0.5525 mL | 1.3813 mL |
Powered by Bioz